Theravance Biopharma
TBPH
113 hedge funds and large institutions have $653M invested in Theravance Biopharma in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 43 reducing their positions, and 16 closing their positions.
157% more call options, than puts
Call options by funds: $2.43M | Put options by funds: $947K
3.56% more ownership
Funds ownership: 92.13% → 95.69% (+3.6%)
5% less funds holding
Funds holding: 119 → 113 (-6)
6% less capital invested
Capital invested by funds: $696M → $653M (-$43.5M)
14% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 43
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Irenic Capital Management
New York
|
+$11.2M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$10.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$9.5M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.85M |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$3.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$10.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.03M |
| 3 |
Two Sigma Investments
New York
|
-$6.41M |
| 4 |
D.E. Shaw & Co
New York
|
-$5.9M |
| 5 |
Millennium Management
New York
|
-$5.67M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Verition Fund Management
Greenwich,
Connecticut
| – | -$126K | -11,261 | Closed |
|
|
MLICM
127
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$45.8K | -4,078 | Closed |
|
|
PMEF
128
Point72 Middle East FZE
Dubai,
United Arab Emirates
| – | -$40.9K | -3,649 | Closed |
|
|
LC
129
Lindbrook Capital
Calabasas,
California
| – | -$1.48K | -132 | Closed |
|
TBPH Hedge Fund Activity: Q1 2023 in Review
113 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2023, worth a combined $653M — down 6.3% from $696M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of TBPH and 10 opened new positions — a net loss of 6 holders — while 43 trimmed existing stakes and 37 added.
The largest buyer was Irenic Capital Management, adding an estimated $11.2M. The largest seller was Baupost Group, cutting an estimated $10.6M.
- 113 institutional investors held Theravance Biopharma (TBPH) as of Q1 2023, down from 119 in Q4 2022.
- Funds reported $653M of Theravance Biopharma stock for Q1 2023, down 6.3% quarter-over-quarter.
- 10 funds opened new Theravance Biopharma positions in Q1 2023 and 16 closed out, a net change of -6 holders.
- The largest Theravance Biopharma buyer in Q1 2023 was Irenic Capital Management, an estimated $11.2M added.
- The largest Theravance Biopharma seller in Q1 2023 was Baupost Group, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2023.